Evrys Bio
Evrys Bio is a pioneering biotechnology company focused on developing broad-spectrum antiviral therapies. Founded on breakthrough discoveries from Princeton University, the company aims to transform the treatment of viral infections by targeting human proteins known as sirtuins. This innovative approach enhances the body's natural immunity, offering a high barrier to drug resistance and addressing multiple viruses simultaneously. Evrys Bio's vision is to provide first-in-class antivirals that are safe and effective against a wide range of infectious diseases, ultimately transforming medical practice by focusing on disease conditions rather than individual viruses.
Patents
Infectious Diseases
Drugs
Routes of Administration
Key People
President & CEO
Founder and Board Director
Vice President - Research
Operations & Strategy (Consultant)
Chief Financial Officer
Chief Business Officer
President & CEO
Founder and Board Director
Vice President - Research
Operations & Strategy (Consultant)
Chief Financial Officer
Chief Business Officer
News & Updates
Evrys Bio will participate in the CBDS&T meeting in December 2024 in Ft. Lauderdale.
Lillian Chiang, CEO of Evrys Bio, presented at the BioCentury’s East-West Biopharma Summit in Boston.
Evrys Bio received $34 million from the Department of Defense to develop a single drug effective against multiple lethal viruses.
An article discussing the broad-spectrum anti-infective activity of drugs targeting Sirtuin 2.
Research on an allosteric inhibitor of Sirtuin 2 that blocks hepatitis B virus DNA establishment and transcriptional activity.
Evrys Bio was awarded a Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease for developing a single antiviral to treat multiple opportunistic infections.
Evrys Bio will participate in the CBDS&T meeting in December 2024 in Ft. Lauderdale.
Lillian Chiang, CEO of Evrys Bio, presented at the BioCentury’s East-West Biopharma Summit in Boston.
Evrys Bio received $34 million from the Department of Defense to develop a single drug effective against multiple lethal viruses.
An article discussing the broad-spectrum anti-infective activity of drugs targeting Sirtuin 2.
Research on an allosteric inhibitor of Sirtuin 2 that blocks hepatitis B virus DNA establishment and transcriptional activity.
Evrys Bio was awarded a Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease for developing a single antiviral to treat multiple opportunistic infections.